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B-cell malignanciesAntisense gene therapy using molecules such as antisense oligodeoxynucleotides, siRNA or miRNA is a very
promising strategy for the treatment of neoplastic diseases. It can be combined with other treatment strategies
to enhance therapeutic effect. In acute leukemias, overexpression of the antiapoptotic gene BCL2 is observed in
more than 70% of cases. Therefore, reduction of the Bcl-2 protein level could, in itself, prevent the development
of cancer or could possibly help sensitize cancer cells to apoptosis inducers.
The main objective of our work is to develop therapeutic liposome formulations characterized by high transfec-
tion efﬁciency, stability in the presence of serum, as well as speciﬁcity and toxicity for target (leukemic) cells.
Each of our liposomal formulations consists of a core composed of antisense oligonucleotides complexed by ei-
ther cationic lipid, DOTAP, or a synthetic polycation, polyethyleneimine, encapsulatedwithin liposomesmodiﬁed
with polyethylenoglycol. In addition, the liposomal shells are enriched with covalently-bound antibodies recog-
nizing a well characterized bio-marker, CD20, exposed on the surface of leukemia cells. The resulting
immunoliposomes selectively and effectively reduced the expression of BCL2 in target cells. Model animal exper-
iments carried out on mice-engrafted tumors expressing the speciﬁc marker showed high efﬁciency of the
liposome formulations against speciﬁc tumor development. In conclusion, we show that lipid formulations
based on a polyplex or lipoplex backbone additionally equipped with antibodies are promising non-viral
vectors for speciﬁc oligonucleotide transfer into human tumor cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer, a large family of diseases, remains a global health problem
and one of the major causes of death worldwide. Whilst it has been
traditionally considered a terminal disease, there is now a growing
opinion that it could become a manageable chronic disease, rather
than a terminal acute illness. However, this requires long-term pharma-
cological intervention and has forced major shifts in cancer therapy
approaches, particularly in recent years, resulting in new and more
effective therapeutic strategies. Nucleic acid molecules such as anti-
sense oligonucleotides (DNA or RNA), small interfering RNAs (siRNA,
miRNA) or oligonucleotides with catalytic activity (DNAzymes,
ribozymes) can be used to inhibit the expression of particular genes
either as a monotherapy, or in combination with other non-gene
therapeutic agents, to enhance their effectiveness [1,2]..
. This is an open access article underAntisense oligonucleotides (asODNs) usually consist of 15–20
nucleodides which are complementary to their target mRNA or the
DNA sequence of a particular gene or its promoter. Two major mecha-
nisms of antisense activity have been described. The ﬁrst is the activa-
tion of RNase H, which digests the mRNA moiety of a DNA–RNA
heteroduplex. Moreover, asODNs that do not induce RNase H activity
can hybridize to mRNA and block its access to the ribosome. Antisense
oligonucleotides may also bind to DNA sequences to form triple-
helical structures, thus distorting transcription [3–5].
Although the idea to reduce translation by oligonucleotides comple-
mentary tomRNA is simple, several issues need to be solved for success-
ful application of antisense molecules as therapeutics. Extra- and intra-
cellular obstacles must be overcome in order to achieve selective and
effective nucleic acid delivery into target cells and tissues. These include
anatomical barriers such as epithelium, endotheliumand the extracellu-
lar matrix. Surrounding cells also may prevent nucleic acids to reach
target cells. In addition, various nucleases are present in the blood
and, therefore, protection against enzymatic degradation of the nucleic
acids is also crucial [6]. Solving these problems can be achieved bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Abbreviations and description of liposomal formulations used in this study.
Abbreviation Name/term Description
t Antibody Free anti-CD20 antibodies, Rituximab
L
Non-targeted empty
liposomes
Empty liposomal coat
tL
Targeted empty
liposomes
Empty liposomal coat decorated with
antibodies
L-D
Liposomal coated
DOTAP-asODN complex
Non-targeted liposomes, i.e. without an
antibody coating, carrying anti-BCL2
asODN complexed with DOTAP
tL-D
Targeted liposomal
coated DOTAP-asODN
complex
Antibody-targeted liposomes
(immunoliposomes) carrying anti-BCL2
asODN complexed with DOTAP
tL-Dsc
Targeted liposomal
coated DOTAP-
scrambled asODN
complex
Antibody-targeted liposomes
(immunoliposomes) carrying control
scrambled asODN sequence complexed
with DOTAP
L-P
Liposomal coated
PEI-asODN complex
Non-targeted liposomes carrying
anti-BCL2 asODN complexed with PEI
tL-P
Targeted liposomal
coated PEI-asODN
complex
Antibody-targeted liposomes carrying
anti-BCL2 asODN complexed with PEI
tL-Psc
Targeted liposomal
coated PEI- scrambled
asODN complex
Antibody-targeted liposomes carrying
control, scrambled asODN sequence
complexed with PEI
PE/PC PE/PC nonPEGylated
Control, 100 nm liposomes composed
of PE/PC at a ratio of 60/40 (w/w)
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by the utilization of a suitable nanocarrier system [7,8] Over the last few
years a wide variety of delivery systems for asODNs have been devel-
oped andmany of these are currently undergoing clinical trials. The po-
tential of liposomes as a delivery tool for gene transfer has been
extensively studied for many years and is of particular focus, due to
the recent emergence of encouraging data. They are an interesting alter-
native to viral vectors, which are most effective but characterized by
numerous drawbacks, such as high risk of immunogenicity and the pos-
sibility of unwanted insertion mutations, which eliminate them at the
moment from therapeutic application [9–11]. Liposomes are artiﬁcial
lipid-based vesiclesmade up of one ormore lipid bilayers encapsulating
internal aqueous compartments which can be loaded with nucleic acid
and facilitate its transfer into the cell. Delivery of nucleic acids into
cells occurs primarily liposome uptake via endocytosis and subsequent
fusion processes are involved in the release of the nucleic acid com-
plexes from the endosomal compartment into the cytosol [7,12].
Targeted vectors are increasingly favored tools for speciﬁc delivery
of antisense oligonucleotide-based therapeutics into cancer cells. This
is achieved by functionalizing the carrier with targeting moieties that
exhibit high-afﬁnity towards speciﬁc tumor cells. Monoclonal antibod-
ies [13–15], antibody derivatives [13,14,16], peptides [17,18], and
aptamers [19,20], designed ankyrin repeat proteins (DARPins) [21]
and small targeting molecules [22,23] can be attached to liposomes
and each of them have been reported to exhibit active targeted delivery
[24]. In this regard, chemical modiﬁcations of polyethylenoglycol (PEG)
residues are particularly suitable for conjugation of targetingmoieties to
the surface of liposomes [25].
Here, we present two liposomal formulations designed to
carry nucleic acids, which can be easily targeted to cells exposing
cancer-speciﬁc markers recognized by targeting molecules conjugated
to the liposome surface. One of the formulations is based on a
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane)-asODNs com-
plex (tL-D) and the other is based on a PEI (polyethylenimine)-asODNs
complex (tL-P). Both complexes are encapsulated in a PEG
(polyethyleneglycol)-modiﬁed liposomal coat. Attachment of targeting
molecules was achieved via chemical coupling of antibodies to the
maleimide groups present on the PEG-modiﬁed lipid. These formula-
tions fulﬁll the criteria of size, stability, speciﬁcity and reasonably high
efﬁcacy against speciﬁc types of cancer cells.
2. Materials and methods
2.1. Materials
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane (chloride
salt) N99%; DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine);
HEPC (L-α-phosphatidylcholine, hydrogenated (egg, chicken) N99%;
DC-CHOL (3ß-[N-(N’,N’-dimethylaminoethane)-carbamoyl]cholesterol
hydrochloride) N99% were purchased from Avanti Polar Lipids, Inc.
(USA); DSPE-PEG (N-(Carbonyl-methoxypolyethyleneglycol2000)-
1,2-distearoyl-sn-glycero-3 phosphoethanolamine, sodium salt)
N99%; DSPE-PEG-Mal (N-[(3-Maleimide-1-oxopropyl)aminopropyl
polyethyleneglycol-carbamyl] distearoylphosphatidyl-ethanolamine)
N99% were purchased from NOF Corporation (Japan). Further reagents
were: OPD, o-phenylenediamine (Sigma Aldrich (Germany); PEI
(Polyethylenimine) (Polyscience, Inc. USA); BCA Protein Assay Reagent
(Thermo Scientiﬁc, USA); Hanks liquid medium (Institute of Immunol-
ogy and Experimental Therapy, Polish Academy of Science, Wroclaw,
Poland); Matrigel (BD, Immunogen); plasmid pMaxGFP (Lonza);
Rituximab, therapeutic anti-CD20 antibodies MabThera (Roche); anti-
human Bcl-2 mouse monoclonal antibodies (Santa Cruz, USA and
Abcam, USA); anti-human Actin goat polyclonal antibodies (Santa
Cruz, USA); horseradish peroxidase-conjugated goat anti-mouse and
donkey anti-goat IgG (Santa Cruz, USA); Sepharose 4B and Sephadex
G-100 (Sigma-Aldrich); mitoxantrone 2 mg/ml (Hospira, UK, Ltd.);calcein (POCH S.A.R); DNase I (RNase-free, MnCl2) (Fermentas, Thermo
Scientiﬁc); MTT (Sigma-Aldrich, Life Science); DiD 1,1′-Dioctadecyl-
3,3,3′,3′-tetramethylindodicarbocyanine (Thermo Fisher Scientiﬁc),
DiO 3,3′-dioctadecyl-oxacarbocyanine perchlorate (Thermo Fisher
Scientiﬁc); Traut's reagent ≥98% (TLC) (Sigma-Aldrich, Life Science);
agarose (Prona); Ficoll Paque (GE Healthcare Life Technologies, Inc.).
Antisense oligonucleotides (asODNs) anti-BCL2 mRNA of the following
sequence: 5ʹ TCT CCC AGC GTG CGC CAT 3ʹ and scrambled sequence: 5ʹ
CAG CGTGCG CCA TCC TTC CC3ʹwere synthesized by Genomed, Poland.
2.2. Cells
Human Daudi (CCL-213) and Raji (CCL-86) B-cell lines and white
blood cells isolated from peripheral blood (permission number KB -
542/2011 of the Ethics Committee at the Medical University of
Wroclaw) were used as a model of target cells. Jurkat T-cells, HL60
and HEL cell lines were used as negative (CD20-) control cells. All cell
lines were obtained from the Cell Culture Collection, Institute of Immu-
nology and Experimental Therapy, Polish Academy of Science at
Wroclaw. Cells were cultured in vitro in RPMI 1640 medium (Lonza)
supplemented with 10% fetal bovine serum (Lonza), 2 mM glutamine,
100 U/mL penicillin and 100 μg/mL streptomycin (Lonza) at 37 °C in a
humidiﬁed atmosphere.
2.3. Liposome preparations
All types of liposomes studied in this report, prepared as described
below, are listed in Table 1, as are abbreviations of the controlmolecules
used.
2.3.1. L-D Liposomes
The formation of DOTAP/asODN complexes was carried out by using
a Blight and Dyer extraction [26] in a glass test tube. Cationic lipid,
DOTAP (2 mg), was diluted in 150 μl of chloroform to which 400 μl of
methanol was added, followed by 100 μg of ODNs or plasmid DNA
(pMaxGFP Lonza) diluted in 150 μl of H2O. The mixture was incubated
for 40 min at room temperature. Subsequently, 300 μl of chloroform
and 300 μl of H2O were added, and the tube was centrifuged for 8 min
at 800 ×g, at room temperature, followed by centrifugation and remov-
al of the upper aqueous phase. Chloroform solutions of HEPC, DOPE, DC
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weight ratio of 2.8:1:0.4:0.8:0.34 and then added to the remaining
lower organic phase. Then, 1 ml of PBS was added to the mixture, and
the resulting mixture was sonicated for 1 min to obtain a stable emul-
sion. In the case of the ﬂuorescently labeled liposomes, DiD was added
to the emulsion after the sonication step at a ﬁnal concentration of
0.1 mol%. The organic solvent was evaporated under gaseous N2 and
vacuum-dessicated for at least 2 h. The gel phase was hydrated with
1 ml of PBS for 1 h by gentle stirring at room temperature. The resulting
liposome suspension was then extruded 10 times through polycarbonate
ﬁlters with pore sizes of 400, 200 and 100 nm in a sequential way. This
protocol typically yielded 1 ml of liposomes at a ﬁnal lipid concentration
of 10 mg/ml containing 90 μg ODNs or plasmid DNA.
2.3.2. L-P liposomes
In order to prepare polyplexes, 100 μl of asODNs dissolved in water
at 1 μg/μl were mixed with 200 μl of linear PEI (2500 Da) solution in
water to obtain a N/P (PEI/DNA) ratio of 5:1. 100 μl of 10× PBS was
then added and the mixture made up with water to 1 ml. The mixture
was then incubated at room temperature for 30 min. Chloroform solu-
tions of lipids HEPC, DOPE, DC-Cholesterol, DSPE-PEG and DSPE-PEG-
Mal, in a weight ratio of 2.8:1:0.4:0.8:0.34 were premixed together,
dried under a stream of nitrogen and kept under vacuum for at least
2 h to completely remove the solvent. The lipids were then hydrated
with the 1 ml asODNs:polyethylenimine complex in PBS. As described
above, in the case of ﬂuorescently labeled liposomes, DiD was added
to the mixture at a ﬁnal concentration of 0.1 mol%. The liposomal sus-
pension was then extruded through a series of polycarbonate ﬁlters of
400, 200 and 100 nm pore size, respectively. This protocol typically
yielded 1 ml of liposomes at a ﬁnal concentration of 8 mg/ml of lipids
containing 90 μg of ODNs or plasmid DNA.
2.3.3. tL-D and tL-P liposomes
In order to attach the respective targeting-antibody to the liposomal
surface, free amino groups on the antibodieswere thiolated by exposure
to Traut's reagent for 4 h at 4 °C in PBS. The Traut's reagentwas removed
by dialysis into PBS buffer. The thiolated antibody was incubated for
24 h with a suspension of L-D or L-P liposomes in PBS containing
DSPE-PEG-Mal in the liposomal coat. The speciﬁc reaction conditions
were designed to achieve a molar ratio of 13:1 for the DSPE-PEG-Mal
in the liposomal coat relative to the amount of IgG used. Unbound anti-
bodies were separated from liposomes via size-exclusion chromatogra-
phy on a Sepharose 4B column (1.25 × 25 cm) and the ﬁnal antibody-
coated liposomes equilibrated in PBS. A schematic representation of
the preparations is included in Fig. 1.Fig. 1. Schematic model of liposomal formulatio2.3.4. PE/PC (60/40) non-PEGylated control, empty liposomes of 100 nm in
diameter
These liposomeswere prepared by a simple procedure involving hy-
dration of dry lipid ﬁlm prepared from the 60:40 mixture of PE and
HEPC (60:40 by weight) in PBS and systematic extrusion through
Nucleopore ﬁlters, as was described above.
2.3.5. Determination of the antibody fraction attached to the liposome
surface
A 96-well plate dedicated for ELISA (Greiner Bio One) was exposed
to 4 μg of polyclonal rabbit anti-human IgG (Jackson ImmunoResearch)
in 100 μl of PBS per well. The plate was incubated overnight at 4 °C,
washed, and the coated surface was then blocked with 5% non-fat
milk in PBS. Then tL-D or tL-P immunoliposomes were added and
incubated for 1 h at 37 °C. Subsequently, the plate was washed and
incubated for 45 min with a secondary antibody, namely rabbit anti-
mouse IgG conjugated with HRP (Jackson ImmunoResearch), at a dilu-
tion of 1:5000. After further washing with PBS, HRP substrate
(0.05% o-phenylenediamine (w/v) and 0.1% H2O2 in citrate buffer,
pH 5.0) was added. The result was read on a multiwell plate reader
(Rayto) at a wavelength λ= 490 nm.
2.4. Liposome size and zeta potential
The mean diameter, polydispersity index and zeta potential of the
prepared liposomes were obtained by using a Zetasizer Nano-ZS
(Malvern Instruments, Malvern, UK).
2.5. Calcein release
L-D or L-P liposomes loaded with 30 mM calcein were prepared
without the DOTAP-DNA or PEI-DNA complexes according to the stan-
dard procedure until the hydration of gel phase of L-D or dried lipid
ﬁlm of L-P. The liposomes were rehydrated in 30 mM calcein solution
after which the lipid suspension was frozen in liquid nitrogen and
thawed at 56 °C. After 10 such freeze–thaw cycles, free calcein was
removed by passing the liposome suspension through a Sephadex
G-100 column (12 × 1 cm) and liposomes were downsized by the
extrusion. Stability of barrier properties of liposomal shells upon
0.5–8 h exposure to 50% human serum at a temperature of 37 °C
was examined. The ﬂuorescence of the calcein was measured with
a (Carry Eclipse, Varian) spectroﬂuorometer at λex = 490 nm and
λem = 520 nm. Calcein leakage was calculated according to the fol-
lowing formula: % Release = (Ft− F0) / (Ftotal− F0) × 100, where Ft
was the ﬂuorescence of calcein after incubation with serum at time
t = 0.5–8 h, F0 was the spontaneous leakage at time t and Ftotal wasns tL-D and tL-P encapsulating nucleic acid.
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10% Triton X-100.
2.6. Protective properties of the liposome formulations against nucleic acid
digestion by DNases
Liposomal suspensions containing 1 μg of plasmid DNA (pDNA) that
had been stored for one year were incubated with 0.1 U of DNase I for
10 min at 37 °C. After this time the DNase I was inactivated by heating
at 65 °C for 10 min in the presence of 50 mM EDTA, pH 7.5. In addition,
the protective properties of liposome preparations against DNases was
examined via exposure of liposomes to 50% human serum for
incubation periods ranging from 1 to 8 h at a temperature of 37 °C. For
both assays, liposomes were subsequently separated on a Sepharose
4B microcolumn in order to remove the DNase I or serum proteins,
respectively. The puriﬁed liposomes were solubilized with 10% Triton
X-100 and analyzed by 1% agarose gel electrophoresis. As a positive con-
trol, liposomes were disrupted with Triton X-100 before incubation
with DNase I or serum.
2.7. Toxicity assay
Toxicity assay was performed using theMTT assay in a 96-well plate
format. Cells in the logarithmic growth phase at 1 × 105/ml were incu-
bated for 48 h with increasing concentrations of liposomes, MTO, or
both. At the indicated time, 200 μg of MTT in a volume of 100 μl was
added to the cells and incubated for 4 h at 37 °C. The plates were then
centrifuged at 1000 ×g for 10 min. The supernatant was carefully re-
moved from each well, and crystals of formazan were dissolved in
DMSO at 50 μl/well. The absorbancewas read on amultiwell plate read-
er at a wavelength of λ= 490 nm.
Based on the linear fragment of the cell-survival curves, the Inhibito-
ry Concentration (IC) valueswere determined. The IC10 (ﬁrst inhibitory
concentration) and IC50 (half maximal inhibitory concentration) values
represent the concentrations of a toxic agentwhich reduces the viability
of the cell population by 10% and 50% respectively, compared to non-
treated control.
2.8. Hemolysis assay
Human peripheral blood of healthy volunteers was collected into
anti-coagulant (EDTA)-containing test tubes (Sarstedt S-MonovetteR)
and centrifuged at 800 ×g for 10 min at 4 °C. The supernatant (plasma)
and the layer of leukocyteswere removed and the pellet of erythrocytes
was washed three times with 155 mM NaCl in 10 mM Tris–HCl pH 7.4
(TBS) and then centrifuged at 800 ×g for 10 min at 4 °C. Then, 30 μl of
a 50% suspension of erythrocytes (~7 × 107 cells) in TBS were
suspended in 1 ml of the same buffer and incubated with increasing
concentrations of liposomes (0.1–2 mg/ml) at 37 °C for 2 h. Hemolytic
activity was determined based on the concentration of hemoglobin
(absorbance at λ=570 nm) released from the erythrocyte suspension.
In a control experiment, erythrocytes were suspended in TBS for 2 h at
37 °C, while 100% hemolysis was determined by the dilution of the
same amount of erythrocyte suspension in distilled water and incubated
as above. To calculate the leakage of hemoglobin, the following formula
was used: % Hemolysis = (Ht − H0) / (Htotal − H0)×100, where Ht
was the absorbance of the 800 ×g supernatant of the erythrocyte sus-
pension obtained after incubation with liposomes, Htotal was the absor-
bance of the supernatant of erythrocyte suspension obtained after
incubation in water and H0 was the absorbance of hemoglobin without
liposomes.
2.9. Selectivity of targeted liposome-cell interaction
Jurkat T cells (0.5× 10 6)were incubatedwith 5 nMDiOovernight in
a humidiﬁed atmosphere and mixed with identical number of Daudicells and were then incubated with 0.1 mg/ml DiD-labeled targeted
(t-L), untargeted (L) or irrevelant IgG conjugated liposomes (IgG-L)
for 1 h at 37 °C. Immediately after the incubation unbound liposomes
were removed by centrifugation and washing in PBS. Flow cytometry
(BD FACS Calibur, BD Biosciences) was used to quantify the targeting
potential of immunoliposomes. Cells were analyzed for DiO (530 nm,
FL-1) and DiD ﬂuorescence (633 nm, FL-4) based on 10,000 counts for
each population. Mean ﬂuorescence intensity as positive cell percent-
ages were determined.
2.10. Bcl-2 protein level determination
To assess the effect of the proposed carriers on Bcl-2 expression,
Daudi cells in the logarithmic growth phase were harvested, washed,
aliquoted into 12-well multi-plates (1 × 106 cells/ml) and incubated
for 48 h with liposomes. At the indicated times, cells were harvested
and lysed.
2.11. Apoptosis determination
Cells (1 × 106 cells) were incubated with 0.1 mg of liposomes/ml
(tL-P or tL-D) for 48 h. At the indicated times, cells were harvested,
washed twice with cold PBS and then suspended in a binding buffer.
Cellswere incubatedwith FITCAnnexin V and Propidium Iodide accord-
ing to themanufacturer's protocol (FITC Annexin V Apoptosis Detection
Kit I, BD Pharmingen) and analyzed by ﬂow cytometry using a BD FACS
Calibur (BD Biosciences) for FITC (530 nm, FL-1) and PI ﬂuorescence
(670 nm, FL-3) based on 10,000 counts for each population.
2.12. Cytokine assay
Human peripheral mononuclear blood cells (2 × 106 cells/ml) were
incubated with 5 μg/ml of free asODNs anti-BCL2 or free ‘scrambled’
ODNs and the same dose of ODNs encapsulated in tL-D or tL-P lipo-
somes (0.5 mg liposomes/ml) for 24 and 48 h in a humidiﬁed
atmosphere. At the indicated times, cells were centrifuged and
supernatants were collected. Levels of interleukin 6 (IL-6) and tumor
necrosis factor α (TNF-α) were measured using a Human IL-6
Quantikine ELISA Kit and a Human TNF-alpha Quantikine ELISA Kit
(R&D Systems, UK), according to the manufacturer's instructions.
Measurements were performed using a microplate reader (BMG
Labtech, Poland). The results were expressed as the ratio of protein
weight/supernatant volume (w/v).
2.13. Animals
Seven to eight-week-old male NOD/SCID mice (weighing 20–25 g)
were obtained from the Children's Clinic Hospital of the Jagiellonian
University at Kraków and maintained under standard pathogen-free
(SPF) conditions. Animal experiments were approved by the First
Local Committee for Experiments with Laboratory Animals, Wroclaw,
Poland.
2.14. Circulation time and biodistribution
NOD/SCID mice-bearing human Burkitt's lymphoma with a mean
tumor volume of 1000 mm3 were administered in the lateral tail vein
with DiD-labeled (0.1 mol%) liposomal preparations of tL-D, tL-P and
control L-P, L-D, and PE/PC (L) in a volume of 10 μl per 1 g of body
weight. Mice were sacriﬁced and blood was collected from the orbital
sinus into a sample tube without EDTA using a capillary at 1, 8 and
24 h after administration of liposomes, and the collected blood then in-
cubated for 2 h at room temperature. Plasmawas separated by centrifu-
gation for 5 min at 2000×g at room temperature. The ﬂuorescence of
DiD in the plasma was measured using a Cary Eclipse (Varian) spectro-
ﬂuorometer at λex = 644 nm and λem = 665 nm. The results were
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cence at the initial time (immediately after injection).
In order to determine the localization of liposomes in CD20+ tumors,
micewere sacriﬁced after 4 and 24 h post-injection and tumorswere re-
moved and washed. Analysis of DiD ﬂuorescence intensity associated
with liposomes in tumors was carried out using the Carestream version
X instrument (FX Pro Carestream, USA), ex. = 630 nm, em. = 700 nm.
Focal plane: 0.0, f-stop: 2.80. Exposure time was 10 s.
2.15. In vivo study of antitumor properties of immunoliposomes in mice
bearing tumor xenografts
Liposome formulationswere prepared in PBS as described above and
administered to mice at a dose described in Table S1, Supplementary
Material. Daudi cells cultured in vitro, as described before, were
suspended in medium (Matrigel:Hanks liquid ratio of 1:1) and injected
subcutaneously (s.c.) in the left ﬂank of each animal (5 × 106 cells in
0.2 ml medium/mouse). When the tumor volume reached 50–
70 mm3, the animals were randomly divided into six equal groups
with eight mice in each. Each group was injected with either the tL-D,
tL-P, tL-Dsc, tL-Psc or t intravenously (i.v.) into the tail vein of the animal
three times at weekly intervals. When used, MTO was administered in-
traperitoneally (i.p.) at a dose equivalent to 0.3 mg/kg body mass. The
control group received PBS. A detailed list of treatments received by
each group of animals is presented in Table S1. Therapeutic efﬁcacy
for each treatment was assessed as a reduction of tumor volume of
the treated mice compared to the control groups i.e. those which did
not receive tL-D or tL-P. The tumor volume was monitored over the
course of the experiment, with measurements performed three times
per week during 70 days of experiment. The tumor volume was calcu-
lated according to the ellipsoid volume formula: tumor volume
(mm3) = (a2 × b) / 2, where a = small tumor diameter in millimeters
(width) and b = large tumor diameter in millimeters (length). The av-
erage body-weight change (BWC) in all of the groups was calculated
using the formula BWC = (ABWn/ABW1) × 100–100%, where ABWn
is the average body weight on day ‘n’ of the experiment (during treat-
ment), and ABW1 is the average body weight on the ﬁrst day of
treatment.
2.16. Data analysis
Statistical analysis was performed using Statistica version 7.1 soft-
ware (StatSoft, Tulsa, OK, USA). Values were expressed as means ±
S.E. for all experiments. Signiﬁcance of differences between the treat-
ments and the control were examined by the Kruskal–Wallis analysis
of variance multiple-comparison P-value test. All tests of statistical sig-
niﬁcance were two-sided, and p b 0.05 were considered as statistically
signiﬁcant.
3. Results
3.1. Stability of the liposomal formulations
3.1.1. The physicochemical properties of the liposomal formulations are
stable during long-term storage
It is assumed that, for efﬁcient extravasation from the fenestrations
in leaky vasculature of tumor, liposomes designed for in vivo applica-
tions should retain a diameter much less than 400 nm [28,29] and dem-
onstrate low polydispersity. The particle size in the case of both
formulations presented here did not exceed a diameter of approximate-
ly 150 nm, even after attachment of antibodies to their surface and the
PDI (the polydyspersity index) [27]was lower than 0.03 for both formu-
lations. Both formulations were stable in terms of particle size during
long-term storage as a suspension or in the form of a freeze-dried pow-
der (Fig. 2A). Both formulations were also characterized by a small pos-
itive zeta potential in water and this parameter also did not changesubstantially during the 12month storage period, either as a suspension
or in the form of freeze-dried powder (Fig. 2B). The effectiveness of the
nucleic acid encapsulation within the presented liposomal constructs
was rather high, about 90%, compared to the total amount added to
the mixture during the preparation procedure. In this case, it means
that 1mgof L-D liposomes contains approximately 9 μg of ODNs or plas-
mid DNA and 1mg of L-P liposomes contains approximately 11.25 μg of
ODNs or plasmid DNA. Moreover, our liposomal formulations remained
stable in terms of their nucleic acid content even after 12 months of
storage (Fig. 2C). In summary, the diameter of liposomes of both formu-
lations increasedmaximally by 20 nmand zeta potential changed in the
range 5 mV over a 12 month storage period. Formulations also main-
tained a very high (over 80%) content of nucleic acids during one year
storage, both in the form of a freeze-dried powder and suspensions.
The average amount of antibodies conjugated to the liposomal enve-
lope was equal to 10.8 ± 1.4 μg/mg liposomes, as determined by ELISA.
Immunoliposomes tL-D and tL-P containing attached anti-CD20 anti-
bodies were stable as a suspension in terms of particle size (increase
in the particle diameter was by 20 ± 3.8 nm, n = 4) during 12 months
of storage. Zeta potential changed in the narrow range 1.8 ± 0.26 mV.
The attachment of antibody to the surface of tL-D and tL-P liposomes
had no effect on the liposome stability and content of nucleic acid,
even after 12 months of storage as a suspension.3.1.2. Liposomal bilayer is stable in the presence of human plasma and
serum
The resistance of the liposomal bilayer against many different active
proteins in plasma, such as components of the complement system or
soluble enzymes, including nucleases, plays a major role in maintaining
the stability of the proposed drug carriers and their function as protec-
tors of active substances loaded internally. As shown in Fig. 2D, both li-
posomal formulations are stable in the presence of 50% human plasma.
Calcein leakage is lower than 10%, even after 8 h of incubation, which
conﬁrms rather high stability of liposomal coat.3.1.3. Liposomes effectively protect encapsulated plasmid DNA against
DNases
The chemical nature of nucleic acids necessitates a suitable carrier
system as protection from enzymatic digestion and without changing
their therapeutic properties, as well as enabling efﬁcient delivery into
targeted cells. To test the protective features of the proposed liposo-
mal formulations, both were incubated in the presence of commer-
cial DNase I. In Fig. 2E and F the data for liposomes stored for 12
months are presented. As can be seen, lipid bilayers of L-D and L-P li-
posomes effectively protect plasmid DNA against DNase I (Fig. 2 E).
Moreover, the liposomal formulations were incubated with 50%
human serum in order to test their resistance against lytic factors
and nucleolytic enzymes present in serum. Both formulations exhibit
high protective properties of encapsulated DNA against serum nucle-
ases (Fig. 2F).3.2. Efﬁciency of liposomes in vitro
3.2.1. The liposome coat shows only limited toxicity
3.2.1.1. The hemolytic activity against human erythrocytes.One of the ele-
ments of non-speciﬁc cytotoxic activity, an important parameter of a
potential liposomal drug carrier, is the hemolytic activity associated
with the treatment itself. Hemolytic activity of liposomes was assessed
by examining the leakage of hemoglobin from erythrocytes after incu-
bation with L-D and L-P containing control plasmid DNA. As can be
seen, the leakage of hemoglobinwas lower than 10% after 4 h of incuba-
tion with liposomes (Fig. 3A), which suggests a very low level of hemo-
lytic activity for these preparations.
Fig. 2. The stability of L-D and L-P liposomal formulations. The distribution of particle size A), zeta potential B) and content of the nucleic acid C) in initial liposomes (white bars), after 12
months of storage in the suspension (black bars) and as a freeze-dried powder stored for 12months (gray bars). Error bars:±standarddeviation (n=10). D) The stability of the liposomal
bilayer in the presence of 50% human serum as a function of calcein leakage during 8 h of incubation. Error bars: ±standard deviation (n= 5). Protective properties of liposomes towards
encapsulated pDNA after incubationwith E) DNase I or F) 50% human serum. NC—negative control (liposomes+10% TritonX-100), PC—positive control (liposomes+10%Triton X-100+
DNaseI or 50% human serum), Ex—experimental sample (liposomes+DNase or 50%human serum+10% TritonX-100),M—molecularmassmarker. For further details seeMaterials and
methods section.
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the carrier for a drug, should not be toxic to non-target cells. The cyto-
toxic activity of L-D and L-P liposomes containing control plasmid
DNA was tested via an MTT assay on several cell lines, namely, Jurkat
T, HEL, and HL60 cells as well as white blood cells (WBC) isolated
from the peripheral blood of healthy volunteers (Fig. 3B). Based on the
initial linear portion of the cell-survival curves, IC10 values were calcu-
lated. Both liposomal formulations exhibited low non-speciﬁc cytotoxic
activity, estimated on the basis of IC10 values, ranging between 0.2–1
mg/ml. The viability of each of the cell populations analyzed was re-
duced maximally by 30% after incubation with the highest concentra-
tion of liposomes (2 mg/ml) carrying control plasmid DNA.
3.2.2. tL-D and tL-P show speciﬁc cytotoxicity either alone or in combination
with a cytostatic drug
We investigated the cytotoxicity of the tL-D and tL-P
immunoliposomal preparations towards target Daudi (CD20+) versus
control Jurkat T (CD20-) cell lines. The results, presented in Fig. 4A, indi-
cate that increasing concentrations of the liposomal formulations signif-
icantly reduce survival of target cells in culture. This effect is much
stronger towards the CD20+ expressing Daudi cells than towards
Jurkat T cells, which do not express this antigen. These experiments
were also conﬁrmed by the results obtained from the selectivity ofinteraction of DiD-labeled immunoliposomes with target cells mixed
with non-target cell population (Fig. 4 B).
Molecules, such as antisense oligodeoxynucleotides can be used to
inhibit particular gene expression in monotherapy, or, in combination
with other therapeutic agents to enhance the effectiveness of non-
gene therapy. Thus, the efﬁciency of our liposomal formulations in a
combined treatment with mitoxantrone (MTO) was examined.
Table 2 presents effective doses of liposomes against 50% of the treated
population (IC50) and 90% (IC90), either alone or in the presence of
12.5 nMMTO. As can be seen, liposomal formulations exerted a stronger
effect in combination with MTO than liposomes alone, with the corre-
sponding IC50 values about two-fold lower for the liposomes in the
combination therapy compared to liposomes alone (Table 2). It should
also be noted that long-term storage of both formulations did not sub-
stantially affect their speciﬁc cytotoxicity. The increase in IC50 values
in both cases was not greater than 10% (Table 2, values in parentheses).
3.2.3. Liposomes targeted with antibody show speciﬁcity in cell–surface
interaction in contrast to untargeted liposomes
Selectivity of immunoliposomes was evaluated by comparing cellu-
lar binding of DiD-labeled targeted or untargeted liposomes in Jurkat T
cells labeled with the ﬂuorescent lipid dye DiO and Daudi unlabeled
cells mixed together and incubated with liposomes. Untargeted
Fig. 3. The liposome coat shows low cytoxicity in vitro. A) The hemolytic activity was tested by determining hemoglobin released from erythrocytes after incubation with increasing con-
centrations of L-D (triangles) and L-P liposomes (squares). The absorbance of hemoglobin released from erythrocytes suspended in water was assumed as a measure of 100% hemolysis.
B) The non-speciﬁc cytotoxicity of liposomes L-D and L-P containing irrelevant nucleic acid (pDNA) towards HL-60, HEL, and Jurkat T cell lines and also humanWBC performed by MTT
assay. Error bars: ±standard deviation (n = 5). For further details see Materials and methods section.
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cluded as a control in these experiments.
We noted high speciﬁcity of tL-cell surface interactions. Approxi-
mately 5–9% of Jurkat T and almost all Daudi cells in mixed population
emitted DiD ﬂuorescence, resulting from binding of tL indicating that
targeting efﬁciency of tL-P towards Daudi cells was considerably higher.
The interaction of tL-P with target cells was also much higher when
compared with this of untargeted (L) or liposomes bearing irrelevant
immunoglobulin (IgG-L) (Fig. 4B). These data indicate amuch higher ef-
fectiveness of interaction of liposomes coated with speciﬁc antibody
with target cells. Similar results were obtained in confocal microscopy
observations of target and non-target cells after incubation with
immunoliposomes (Fig. S3). A certain level of “nonspeciﬁc” interactions
of immunoliposomes with nontarget cells (Fig. 4B) is associated with
the rather high afﬁnity of untargeted liposomes of similar composition
to cells growing in suspension [30]. This relatively high cell surface-
binding activity also visible in vitro cytotoxicity Fig. 4A does not howev-
er, translate into comparably high therapeutic efﬁcacy of untargeted li-
posomes ([30] and Fig. S4). Selectivity of surface-interaction in principle
results in maximal in vitro cytotoxicity observed towards target,
CD20+ cells (Fig. 4A and Table 2). Also, in the presence of low dose
(12.5 nM)mitoxantrone IC decreased to about 50% of the value in its ab-
sence (Table 2).
3.2.4. tL-D and tL-P liposomes reduce Bcl-2 protein level in target cells.
The main function of liposomes as carriers for antisense oligonucle-
otides is targeted delivery, followed by downregulated level of the
protein of interest by the antisense oligonucleotides themselves. As
mentioned above, in our model we chose BCL2 as a target gene, which
is highly overexpressed in many kinds of leukemia and B-cell
lymphomas. We investigated the effect of tL-D and tL-P on Daudi cells.
As can be seen in Fig. 4C, both liposomal formulations effectivelydownregulated the level of Bcl-2 protein in the Daudi cell line after
48 h treatment at a dose of 0.1 mg liposomes/ml (which is equal to
1 μg asODNs anti-BCL2/ml), in contrast to liposomes encapsulating
scrambled antisense oligonucleotide sequence at the same concentra-
tion, which showed no response. We did not observe signiﬁcant differ-
ences in the silencing abilities of antisense encapsulated in fresh and
one year stored liposomal formulations (see Fig. S6). Antisense oligonu-
cleotides encapsulated in untargeted liposomes exerted smaller effect
on Bcl-2 protein level than these encapsulated in targeted ones. As we
previously described [30] the clear inhibition of Bcl-2 mRNA expression
in Daudi cells by antisense encapsulated in untargeted liposomes occurs
after incubation with 5 μg ODNs/ml.
3.2.5. tL-D and tL-P liposomes induce apoptosis in target cells
Daudi cells were incubatedwith tL-D, tL-P or control tL-Dsc, tL-Psc at
a concentration of 0.1mg liposomes/ml for 48 h. Apoptosis and necrosis
levels in treated cell populations were determined by ﬂow cytometry
after Annexin V-FITC and propidium iodide (PI) staining. After 48 h of
culturewith tL-D and tL-P about 85% of cells were Annexin V and PI pos-
itive, indicating that therapeutic activity of the liposomal formulations
containing asODNs against BCL2 is based on the induction of apoptosis.
In non-target control cells incubated with tL-Dsc and tL-Psc liposomes,
only 0.1–2% of the cell populations were Annexin V and PI positive,
whereas the major population of cells were Annexin V and PI negative,
indicating that they were viable and not undergoing apoptosis (Fig. 4D).
3.2.6. The effect of tL-D and tL-P liposomes on IL-6 or TNF-α release by
human PBMCs is markedly reduced compared to free ODNs
Antisense nucleotides, in particular those containing CpG islands can
induce inﬂammatory and immunological response in patients' cells. We
examined if anti-BCL2 asODNs could directly stimulate mononuclear
cells isolated from human peripheral blood (PBMCs) to produce
Fig. 4. Selectivity and efﬁcacy of tL-D and tL-P in vitro. A) The viability of target Daudi (CD20+) and non-target Jurkat T (CD20-) cell lines as a function of liposome concentration. Error
bars: ±standard deviation (n = 5). B) Cellular binding of DiD labeled targeted (t-L) or untargeted (L) liposomes in Jurkat T (non-target) labeled with DiO and Daudi (target) unlabeled
cells mixed together. Untargeted liposomes (L) or irrevelant IgG conjugated liposomes (IgG-L) were included as a control. Quadrant legends: upper left, Jurkat T cells— DiO ﬂuorescence;
upper right, Jurkat T cells binding liposomes — DiO and DiD ﬂuorescence; lower left, non ﬂuorescent Daudi cells; lower right, Daudi cells upon binding liposomes — DiD ﬂuorescence.
Depicted in each quadrant are the percentages of cell emitting ﬂuorescence. C) Bcl-2 protein level in Daudi cells after 48 h of incubation with L-D, L-P, tL-D and tL-P liposomes at a
dose of 1 μg asODNs/ml and control treatments of L-Dsc, L-Psc, tL-Dsc or tL-Psc carried scambled ODNs (scODN) at the same dose. A Western blot was performed by using primary
mouse monoclonal antibodies against human Bcl-2, goat polyclonal antibodies against human beta-actin and rabbit anti-mouse, donkey anti-goat IgG conjugated with HRP as secondary
antibodies. D) Determination of apoptosis/necrosis after 48 h of incubation with tL-D or tL-P (0.1 mg/ml) or control, tL-Dsc or tL-Psc. Daudi cells were labeled with annexin V-FITC and PI
and analyzed by ﬂow cytometry. 1—necrosis, 2—late apoptosis, 3—viable, 4—early apoptosis. For further details see Materials and methods section and the text.
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would also exhibit this activity. Levels of IL-6 and TNF-α were
determined via ELISA in supernatants obtained from the human PBM
cells after 24 and 48 h of incubation with tL-D and tL-P as well as with
free asODN. As shown in Fig. 5, free oligonucleotides exhibit some
immunostimulatory effects associatedwith cytokine IL-6 and TNF-α re-
lease. This effect was approximately three to four-fold smaller uponencapsulation of the asODN into tL-D and tL-P liposomes. This ratio
remained essentially similar when tested after 24 and 48 h. The results
indicate a relatively low immunostimulatory effect of the proposed
formulations.
In conclusion, the in vitro assays indicate that the proposed tL-D and
tL-P formulations selectively recognize CD20+ cells and induce their
apoptosis via BCL2 gene silencing. Moreover, the low doses of
Table 2
Cytotoxicity of tL-D and tL-P formulations towardsDaudi cells expressed as IC50 and IC90,
determined in the absence or presence of 12.5 nM of mitoxantrone (MTO). Values shown
aremeans± standard deviation (n=3). In parentheses the data for both formulations af-
ter storage for one year as a suspension at 4 °C are shown.
Formulation IC50 [μg/ml]
(after one year storage)
IC90 [μg/ml]
(after one year storage)
tL-D 164 ± 11
(172 ± 18)
387 ± 9
(412 ± 9)
tL-D + MTO 83 ± 5 283 ± 15
tL-P 134 ± 18
(144 ± 12)
331 ± 23
(364 ± 14)
tL-P + MTO 62 ± 12 212 ± 21
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PBM cells were treated with the proposed formulations, the levels of
IL-6 or TNF-α released were remarkably lower compared with the
levels released upon treatment of these cells with free asODNs.
3.3. Efﬁciency of liposomes in vivo
3.3.1. 3.3.1. tL-D and tL-P liposomes are long-circulating and accumulate in
CD20+ tumor tissue
3.3.1.1. Blood circulation kinetics. Modiﬁcation of the liposome surface
with PEG is important for ensuring a long circulation time of liposomes
and this is, in turn, a prerequisite for liposome accumulation in tumors.
Blood clearance of the various liposomal formulations was determined
as follows. Either DiD-labeled non-PEGylated PE/PC liposomes tL-D, or
tL-P liposomes were injected intravenously into Burkitt's lymphoma
CD20+ tumor-bearing NOD/SCID mice. As can be seen (Fig. 6A), the
plasma clearance time for the tL-D and tL-P formulations ismuch longer
when compared to that of nonPEGylated liposomes. After i.v. injection
of mice, 70–80% of PEG-modiﬁed liposomes remained in the circulation
for 8 h and approximately 30% remained for 24 h, while less than 20% of
PE/PCwere detected at 8 h,with only ~10% at 24 h. Thus, both proposed
tL-D and tL-P preparations fulﬁll the criteria of long-circulating
liposomes.
3.3.1.2. Localization in tumors. Fig. 6B depicts the results of the distribu-
tion of tL-D and tL-P formulations compared with L-D and L-P (all la-
beled with DiD) in tumors originated from CD20+ (Daudi cells)
engrafted into NOD/SCID mice. DiD ﬂuorescence signal in tumors
taken out from all mice sacriﬁced at times ranging between 1 and
24 h after administration of tL-D and tL-P was signiﬁcantly greater
than that for L-D and L-P liposome-treated mice, indicating that coatingFig. 5.Cytokine IL-6 (A) andTNF-α (B) release after induction of humanPBMCsby immunolipos
(see Table 1), free anti-BCL2 asODNs or free scrambled ODNs for 24 and 48 h. Supernatants wer
For further details see Materials and methods section.with a speciﬁc antibody directs the liposomes towards CD20-bearing
tumor cells. High ﬂuorescence intensities of tumors persisted for 24 h
after administration of tL-D or tL-P liposomes, indicating the long-
term accumulation of the immunoliposomes within the tumors. Much
smaller ﬂuorescence of tumors obtained from model mice treated
with L-D, L-P liposomes was observed 24 h after administration,
which supports the targeting effect of surface-bound antibodies in vivo.
Fig. 6C shows the Bcl-2 protein expression level in tumors engrafted
with Daudi cells in vivo. Western blot analysis conﬁrmed downregula-
tion of target gene expression on protein level in tumors derived from
mice treated with anti-BCL2 asODNs encapsulated in tL-D and tL-P lipo-
somes comparedwith the control ODN sequence encapsulated in tL-Dsc
and tL-Psc.
3.3.2. tL-D and tL-P liposomes show high therapeutic efﬁcacy in the human
xenograft murine model.
To evaluate the anticancer potential of the proposed long-
circulating, targeted liposomal formulations for asODNs, NOD/SCID
mice inoculated with the Daudi human Burkitt's lymphoma cell line
were used. On day 4 following tumor inoculation, mice with xenografts
reaching a volume of 50–70 mm3 were randomized for different treat-
ments (see Table S1 andMaterials andmethods section). tL-D or tL-P li-
posomes or control formulationswere injected into the tail veins of each
animal group three times at weekly intervals at doses shown in
Table S1. In order to investigate the therapeutic efﬁcacy of the liposomal
formulations in combination with a cytostatic, MTO was administered
by intraperitoneal (i.p.) injection at a dose of 0.3 mg/kg of body weight
into the three groups of animals. The results of this experiment are pre-
sented in Fig. 7 and in Fig S2. The data indicate a strong effect of the for-
mulations against tumor development under the in vivo conditions.
Mice treated with control preparations including scrambled ODNs se-
quence developed tumors with a volume of 400–1200 mm3 observed
at 61–70 days following tumor engraftment. It appears that the lipo-
some formulations exerted such a strong effect against this tumor,
that therapeutic enhancement due to the combined treatment with a
low dose of MTO could not be observed (See Fig. S2).
It should be noted that neither the therapeutic antibody itself, used
in the concentration corresponding exactly to the concentration present
on the tL-D/tL-P formulations (650 μg/kg bodyweight), nor the same li-
posome formulations carrying scrambled ODNs affected tumor growth.
Also the control L-D and L-P, which were tested here (Fig. S4) showed
rather small effect on tumor growth compared to the effect of the tL-D
and tL-P formulations reported here. It has to be mentioned that L-D li-
posomes which were recently published as a formulation named “L-cL”
[30] showed reasonable antitumor activity but theywere used inmulti-
ple weekly injections so to maintain high concentration of formulation.omes comparedwith free asODNs. Cellswere treatedwith PBS, tL-D or tL-P, tL-Dsc or tL-Psc
e collected and IL-6 (n= 3) and TNF-α (n= 3) release was determined by ELISA analysis.
Fig. 6. Biodistribution of tL-D and tL-P in vivo. A) Blood circulation kinetics. The ﬂuorescence intensity of DiD-labeled conventional PE/PC control liposomes and tL-D and tL-P liposomes in
the blood serumderived from experimental animals at times ranging between 1 and 24 h after administration. The ﬂuorescence intensitywas expressed as a percent of the value obtained
immediately after injection. Excitation atλex=644nm,λem=655nm. Error bars:±standarddeviation (n=3). B). Analysis of DiDﬂuorescence intensities in CD20+ tumors derived from
mice bearing human Burkitt's lymphomawithin 24 h after administration of DiD-labeled tL-D, tL-P and control L-D and L-P. Excitation at λex= 650 nmand λem=700 nm. Exposure time
was 10 s. Image acquisition was performed on a Carestream version X (FX Pro Carestream, USA). C) Western blot analysis of Bcl-2 protein level in tumors derived from NOD/SCID mice
bearing human Burkitt lymphoma (Daudi) treated with tL-D or tL-P or tL-Dsc or tL-Psc liposomes. For further details see Materials and methods section.
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mal formulations at the intended dose of 0.7 mg ODNs/kg of body
weight, as the body weight remained stable during the entire period
of experiment (Fig. S1). Also, histopathological examination of liver,
spleen and lung tissues was carried out to test for any damage to thetissue. On day 70 following the start of the experiment and triple iv ad-
ministration of tL-D or tL-P (at the prescribed doses), animals were
sacriﬁced and tissueswere collected. Tissueswere sectioned transverse-
ly and stained with hematoxylin and eosin. Microphotographs of liver,
lung and spleen were taken. Tissues taken from mice administered
Fig. 7. Efﬁcacy of tL-D and tL-P liposomal formulations in vivo. A) Mice bearing tumor xe-
nografts were treatedwith tL-D or tL-P, tL-Dsc or tL-Psc control liposomes, free antibodies
(t) or PBS. Tumor volume was calculated on the basis of caliper measurements according
to the formula (tumor volume= length × width2) / 2(n = 8). Error bars: ±standard de-
viation (n = 8). For further details see Materials and methods section.
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the appearance of epithelial necrosis or sloughing of epithelial cells,
were detected (see Fig. S5).
In conclusion, experiments carried out on a human tumor xenograft
model characterized by the presence of a speciﬁc surface-marker,
showed high efﬁciency of the proposed drug formulation against specif-
ic tumor development. Signiﬁcantly, no obvious side effects could be ob-
served with either preparation.
4. Discussion
Antisense therapy is considered both a promising and unique strat-
egy amongst many therapeutic approaches to the treatment of neoplas-
tic diseases [31–33]. Particularly advantageous could be the targeted
delivery of asODNs to speciﬁc cells. The aim of the present study was
to construct the DOTAP- and PEI-based liposomal carriers of antisense
oligodeoxynucleotides which could be targeted via coating with a spe-
ciﬁc antibody. Our model was acute lymphoblastic leukemia (ALL) or
lymphoma, a CD20+ cell-based pathology in which overexpression of
the BCL-2 gene is observed. Although use of similar components in
monotherapies or in combined therapy has been reported in the litera-
ture, our formulations showed very high therapeutic efﬁciency along
with only limited adverse immunostimulatory effect that is usually as-
sociated with the antisense oligonucleotide component drug (asODNs)
[34–39]. Our CD20 targeted liposomes were preferentially uptaken by
B-cells, resulting in downregulated BCL2 expression and sensitization
of the target cells to cytostatics in vitro. Moreover, our results demon-
strate an in vivo therapeutic efﬁcacy for B-cell malignancy of CD20
targeted delivery of antisense nucleotide-based drug against BCL2,
encapsulated in the immunoliposomes described here. The enhanced
retention effect enables liposomes and other particles smaller than
400 nm in size to penetrate the tumor-associated endothelia and ex-
travasate into the tumor tissue [40]. Consequently, nanoparticle-based
drug delivery systemswith a deﬁned size range of 10–200 nm are com-
monly used [41]. However, in the case of nontargeted liposomes, the
therapeutic efﬁcacy observed in the animalmodel used by our laborato-
ry was limited ([30] and Fig. S4). The two liposomal constructs present-
ed in this study, namely, tL-D and tL-P, were characterized by a
homogenous particle size of approximately 120 nm and a positive zeta
potential of 22 and 5 mV, respectively. The differences in the values of
the zeta potential between the two liposome formulations arise fromthe physicochemical properties of the complexing agents used for the
asODNs, namely, DOTAP or PEI. DOTAP, as a cationic lipid, is able to in-
corporate into the lipid bilayer, which may account for the higher posi-
tive zeta potential than the tL-P formulation, despite both formulations
having the same liposomal bilayer composition. These two parameters
remained essentially stable for both liposome formulations during
long-term (12 months) storage. The barrier properties of both prepara-
tions facilitated the preservation of the nucleic acid component against
externally added nucleases. Moreover, the formulations described in
these studies are stable in the presence of human serum. Similar prop-
erties were previously observed for the “L-cL” formulation, despite the
signiﬁcant differences in the chemical composition and the lipid molar
ratio [30]. In addition, the tL-D and tL-P formulations presented in this
study essentially did not show hemolytic activity and were character-
ized by low non-speciﬁc cytotoxicity (Fig. 3 A, B). As both formulations
are based on aDSPE-PEG enriched bilayer, they should remain in the cir-
culation for the extended periods. Modiﬁcation with PEG improves the
pharmacokinetics and pharmacodynamics of liposomes by reducing
renal clearance, protecting from enzymatic degradation and limiting
immunogenic and antigenic reactions. Due to the availability of a
range of PEG derivatives and PEG conjugation technologies, PEGylation
strategies could potentially be adapted for each particular application
[42–46]. Indeed, model animal experiments have consistently shown
markedly increased circulation times for PEG-derived liposome formu-
lations, supporting the vital hypothesis that both formulations fulﬁll the
criteria of long-circulating liposomes (Fig. 6).
As a model for testing the properties of the proposed liposomal
formulations we chose the BCL2 gene as a target for downregulation of
expression and CD20+ cancer cells as a speciﬁc target. Antisense nucle-
otides against BCL2, with a sequence corresponding to G3139, along
with a commercially available antibody, Rituximab (mouse:human
chimeric IgG1 anti-CD20 antibody), were chosen as speciﬁc formulation
agents deﬁning the target of the drug. It should be noted that our formu-
lations could also be used as a nucleic acid delivery vehicle in other sys-
tems for which the speciﬁc genes and surface markers are known. By
way of example, in the case of breast cancer, such a targeted delivery
system could exploit the antisense modulation of expression levels of
one of IAP genes with Trastuzumab, as a cell-targeting moiety, respec-
tively. The IAP family members, such as BIRC5 (baculoviral IAP repeat
containing 5), XIAP, cIAP1 and cIAP2 are overexpressed in breast cancer
cell lines or tumors [47]. Currently, antisense oligonucleotides against
BIRC5 (LY2181308) [48] and XIAP (AEG 35156) [49] are in Phase II of
Clinical Trials, and could be used as a genetic drug in breast cancer treat-
ment [50]. In additionHER2 is overexpressed in approximately 20% of all
breast cancers. Trastuzumab, which is a humanized monoclonal anti-
body against HER2, has been the ﬁrst to reach widespread clinical use,
particularly for the treatment of metastatic breast cancer. Resistance
to Trastuzumab is a major clinical problem in the treatment of HER2-
overexpressing breast cancer. Molecular mechanism can be associated
with up-regulation of anti-apoptotic proteins, such as Bcl-2 [51]. As pre-
viously described, the HER2 aptamer-Bcl-2 siRNA conjugates selectively
internalize into HER2-breast cancer cells and silence Bcl-2 gene expres-
sion [52].What ismore, liposomes targeted via antibodies against HER2
receptor enhanced the biological activity of antisense ODNs against
Bcl-2 in BT-474human breast cancer cell line. No antisense effect on cel-
lular level of protein expressionwas detectedwhenODNwas associated
with PEG-coated cationic liposomes. On the contrary, when the corre-
sponding HER2-targeted ODN delivery system was used, a 46% inhibi-
tion of Bcl-2 expression was observed [53].
Again, a similar strategy could be used against acute lymphoblastic
leukemia (ALL) in patients with the Philadelphia chromosome (Ph).
The Philadelphia translocation t(9;22)(q34;q11) generates the bcr-abl
fusion gene, characteristic for chronic myelogenous leukemia (CML)
and Ph + acute lymphoblastic leukemia (ALL) [54]. In the case of ALL,
the presence of the Ph translocation is tightly correlated with poor
prognosis. Small interfering RNAs (siRNAs) or asODNs could be
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acute lymphoblastic leukemia. ALL blast cells express a variety of
speciﬁc antigens, such as CD19, CD20, CD22, CD33, and CD52, that
could serve as biomarker-targets for mAbs [55]. A number of commer-
cially available antibodies such as anti-CD52 (alemtuzumab), anti-
CD22 (epratuzumab), and anti-CD33 (gemtuzumab) are already
available in the clinic that could be used in this regard to target lipo-
somes speciﬁcally to those cells expressing the respective biomarker.
The system of Rituximab and asODNs against BCL2 is a widely ex-
plored strategy in the treatment of B-cell malignancies. However,
Gekeler et al. [38] demonstrated that the asODN, G3139, contains
two dinucleotide CpG motifs and therefore acted as a potent
immunostimulator in the TLR9 murine model [38]. Yu and co-workers
[56], studying reasons for the limited success of G3139, suggested that
this was due to the low intracellular levels of G3139 achieved in the pa-
tient and the potential stimulation of cells and cytokine release via the
CpGs through TLRs. These authors designed Rituximab-targeted
immunoliposomal nanoparticles, “RIT-INPs”, as carrier for the G3139
antisense oligonucleotide. They used protamine as a complexing
agent, and a liposomal bilayer composed of ePC, DC-CHOL, DSPE-PEG.
G3139 encapsulated in immunoliposomal nanoparticles targeted with
Rituximab (RIT-INPs) showed reduced immunostimulation and high
therapeutic efﬁcacy in the Raji xenograft NOD/SCID model in vivo [56].
The data presented in our study (Fig. 5) indicate substantial limitation
in IL-6 or TNF-α release in human PBM cells after treatment with
tL-D or tL-P, compared to free anti-BCL2 asODNs. In addition, we
used unmodiﬁed oligonucleotides, so there is no possible sequence-
independent toxicity due to usage of phosphorothioate-modiﬁed oligo-
nucleotides [57,58]. Immunoliposomes decorated with antibodies
against CD20 or CD19 have been described previously. For example,
Sapra et al. [59,60] demonstrated improved results of treatment of
tumor-bearing mice with liposome-encapsulated doxorubicin or
vincristine, targeted via anti-CD19 or anti-CD20 antibodies, or their de-
rivatives. Taking into account our previous data [30] alongside the re-
sults presented here, targeting via speciﬁc antibodies signiﬁcantly
improves the therapeutic activity of liposome-encapsulated asODNs.
Based on the ﬁndings of both our own studies and of other promis-
ing preclinical data [56], it would appear that further clinical develop-
ment of liposomal formulations of asODNs against BCL2, such as tL-D
and tL-P, could provide the basis for a highly improved therapeutic in-
tervention in the case of ALL. Drug resistance is a serious limiting factor
in the treatment of cancer. Overexpression of the BCL2 gene is one of the
mechanisms responsible for drug resistance, particularly in human lym-
phoblastic leukemia of B-cells. For these types of leukemia a more so-
phisticated therapeutic strategy needs to be used. One of the reasons
to undertake gene-silencing therapy in leukemia treatment is sensitiz-
ing these cells to standard chemotherapy. Our in vitro experiments
showed an increase of efﬁcacy of a standard cytostatic observed in the
case of Daudi cells (see Table 2). However, targeted delivery of asODNs
against the BCL2 gene, by using the tL-D or tL-P liposomal formulations
aswell as silencing this gene resulted in such a substantial efﬁcacy in its
own right that the expected synergistic effect in the presence of the cy-
tostatic was not observed (see Fig. S2).
The in vitro results presented above, using either the tL-D or tL-P for-
mulations, provided a starting point for investigating the behavior of
these formulations in animal studies. For these experiments we used
NOD/SCIDmice bearing a Daudi tumor xenograft (human Burkitt's lym-
phoma) as a human tumor xenograft model. For the pharmacokinetics
and biodistribution studies, we used liposomal formulations labeled
with lipid-binding dye. The lipophilic carbocyanines, such as DiD, are
weakly ﬂuorescent in water but highly ﬂuorescent when incorporated
into membranes. We have observed only a small (b5%) transfer of DiD
from liposomes to red blood cells (Tab. S2), indicating that transfer of
free dye between liposomes and cells is rather limited. After 24 h, about
30% of the injected drug incorporated within the immunoliposomal
shell was still present in the blood (Fig. 6A). Accumulation ofimmunoliposomes in the tumor could also be observed (Fig. 6B). There-
fore, the biodistribution data indicated that both tL-D and tL-P liposomal
formulations were able to reach and accumulate within their target site
(Fig. 6B). Moreover, the downregulation of BCL2 gene expression in the
tumors was observed after the same time interval (Fig. 6C), conﬁrming
the speciﬁcity of action of the proposed formulations. The results of the
experiment on engrafted tumor treatment with the tL-D and tL-P encap-
sulated asODNs indicate that both liposomal formulations are able to in-
hibit tumor growth by 100%, leading to complete remission in treated
mice (Fig. 7).
The data revealed a very high therapeutic activity of both tL-D and
tL-P liposomal formulations carrying encapsulated antisense oligonu-
cleotides against BCL2 gene under in vivo conditions. Multiple negative
controls, such as PBS, Rituximab (650 μg/kg), tL-Dsc, and tL-Psc, exclud-
ed the antitumor activity of each of the liposomal components separate-
ly. Although some cytotoxicity towards non-target cells could be
observed in vitro, no toxicity was observed in the animal models
in vivo, suggesting that the liposomal formulations (i.e. lipid bilayer
components and complexing agents, DOTAP or PEI) were non-toxic at
the doses used, as no weight-loss, nor any changes in the histology of
major organs was observed in the experimental animals (Fig. S1 and
S5). Taking all of the above considerations into account, it is concluded
that both of the proposed tL-D and tL-P liposomal formulations encap-
sulating antisense oligodeoxynucletides against BCL2 gene expression
appear to demonstrate proof-of-concept for the targeted treatment of
CD20+ cell-based pathologies. While the combination of these lipo-
some formulations with cytotoxic drugs might be the ultimate ap-
proach, it is particularly encouraging to note that the current study
demonstrated the effectiveness of such a targeted-liposome approach
even as a monotherapy.
5. Conclusions
Two formulations of immunoliposomes are proposed in this study,
consisting of a core of antisense oligonucleotides complexedwith either
a cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane, or a syn-
thetic polycation, polyethyleneimine, encapsulated within liposomes
containing a polyethylene-glycol-derivative of distearoyl phosphatidyl-
ethanolamine. The liposomesweremodiﬁedwith covalently-bound an-
tibodies recognizing CD20, a well-characterized bio-marker present on
the surface of leukemia and lymphoma cells. These liposomes maintain
stability for at least one year of storage in suspension, or, as a freeze-
dried powder and effectively protect the encapsulated nucleic acids.
Immunoliposomes developed in our studies effectively reduce the
level of Bcl-2 protein in cancer cells and are selective towards target
cells. In vivo experiments carried out onmice-engrafted tumors charac-
terized by the presence of the speciﬁc CD20 bio-marker showed highly
speciﬁc efﬁciency of the drug formulation against tumor development.
Although single components of the proposed formulations, such as
antisense oligonucleotides and monoclonal antibodies have been used
in other studies, or have been under clinical trials, the mixed formula-
tions proposed here showed a high therapeutic efﬁcacywith only a lim-
ited immunostimulatory effect that asODNs have traditionally suffered
from.
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